Analyst Buy Ratings
Phreesia Maintains Buy Ratings From Multiple Analysts Amid Significant Undervaluation
Anonymous
Key Points
1
RBC Capital reiterates an Outperform rating on Phreesia with a $19 price target; GuruFocus shows the stock around 58.9% undervalued relative to a GF Value of $27.19, with a current price near $11.18 and a GF Score of 66/100.
2
Wells Fargo raised its Phreesia price target to $10 and maintained an Equal-Weight rating.
3
Market-cap estimates for Phreesia show only minor variation across sources, with figures around roughly $679 million to $691 million.
4
In addition to Freedom Capital, Needham and DA Davidson are noted as Buy ratings on Phreesia, indicating broader bullish coverage.
Phreesia, a cloud-based software platform serving healthcare providers, remains undervalued despite broad analyst support. RBC Capital and Freedom Capital maintain bullish ratings with $19 and $14 price targets respectively, while the stock trades around $11—roughly 59% below its intrinsic value estimate of $27.19 GuruFocus. Wells Fargo raised its target to $10 but kept an Equal-Weight rating, reflecting mixed confidence in near-term gains.
The $690 million market-cap company posted 10% Q2 revenue growth and expanded profitability watchlistnews, but insider selling totaled $58,477 over three months—a cautionary signal beneath the positive ratings. Phreesia's integrated platform for patient access and payments continues attracting interest from both optimistic bulls and measured hold-raters.
RBC and Freedom Capital See 40% Upside
RBC Capital reiterates an Outperform rating with a $19 target, implying 70% upside from current levels. Freedom Capital maintains Buy at $14, a 25% gain from here. Together, these two accounts signal meaningful undervaluation and sustained confidence in Phreesia's healthcare software thesis—improved patient access and better outcomes for doctors.
Mixed Signals From Wells Fargo and Valuation Metrics
Wells Fargo raised its target to $10 but kept an Equal-Weight rating—a cautious stance that contrasts with bullish peers. The stock's P/E ratio sits in the mid-70s, pricing in strong growth. Yet GuruFocus estimates intrinsic value at $27.19, leaving a 58.9% margin of safety at $11.18. The GF Score of 66/100 suggests mid-range quality fundamentals beneath headline valuations.
Q2 Growth Sustained Amid Insider Selling Caution
watchlistnews reports Phreesia posted 10% Q2 revenue growth and expanded adjusted EBITDA while maintaining full-year guidance. Yet insider transactions reveal a net $58,477 sell over three months—not alarm-level, but a reminder that executives remain cautious despite positive outlooks. DA Davidson and Needham also rate Buy, broadening bullish coverage beyond Freedom and RBC.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
14
Articles
6
Reach
20
A
AnonymousAuthor
